-

MedinCell Announces Fiscal Year Consolidated Results

MONTPELLIER, France--(BUSINESS WIRE)--Strong consolidated financial position as at March 31, 2020 and strengthened since year-end

  • 12.4 M€ in cash and cash equivalents
  • 3.6 M€ of risk-free financial assets (0.4 M€ current + 3.3 M€ non-current)
  • 10.9 M€ of additional non-dilutive financing (PGE) -Post-closing
  • 3.1 M€ of CIR collected in May 2020 - Post closing
  • 5.0 M€ to be received from the EIB under conditions

Consolidated financial results:

  • Income from ordinary activities: 6.O M€ (+48% compared to the previous year)
  • Cash consumption linked to the activity: 12.5 M€ (in line with expectations)

Evolution of the product portfolio in line with expectations

  • Progress in clinical development: Phase 3 of mdc-IRM (antipsychotic), led and funded by Teva Pharmaceuticals and mdc-CWM (post-operative pain and inflammation), funded by AIC
  • A third product in clinical development: start of Phase 1 of the mdc-TJK (antipsychotic) product led and financed by Teva Pharmaceuticals
  • Two new products in regulatory preclinical studies: mdc-ANG (antipsychotic) and mdc-WWM (contraception), the latter benefiting from a new four-year 19 M$ grant from the Bill & Melinda Gates Foundation
  • Three programs close to formulation selection that paves the way for preclinical development: mdc-GRT (organ transplantation), mdc-NVA (pain) and mdc-KPT (animal health)
  • New program launches:
    • mdc-STM: formulation of a 3-month active injectable of Ivermectin to neutralize the vector of malaria transmission, the program received a 6.4 M$ grant over three years from Unitaid
    • mdc-STG: new internal program in formulation
    • Feasibility study of an injectable long-acting HIV prevention treatment (PrEP) funded by the Gates Foundation

Significant post-closing events related to the product portfolio:

  • Recruitment completed for the mdc-IRM Phase 3 clinical study, interim analysis expected before the end of 2020
  • Completion of the mdc-CWM Phase 2 clinical study, Phase 3 is scheduled to begin by the end of 2020
  • Launch of a research program for Covid-19 prevention (prophylaxis)

Access the complete Press release

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

MedinCell

BOURSE:MEDCL

Release Versions

Contacts

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier
Relations investisseurs
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Nicolas Merigeau
Relations médias
medincell@newcap.eu
+33 (0)1 44 71 94 98

More News From MedinCell

Medincell - UZEDY®: Q3 U.S. Net Sales Reach $85M, Up 96% Year-on-Year; 2026 Revenue Outlook Raised to $290-310M

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: UZEDY® U.S. net sales reached $85M in Q3 2026, up 96% year-on-year, according to third-quarter results reported today by Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals (NYSE and TASE: TEVA). Teva raised its 2026 UZEDY® revenue outlook to $290-$310M, from $270-$290M previously. UZEDY® generated $225M in U.S. net sales over the first nine months of 2026, exceeding the $191M reported for full-year 2025. UZEDY® commercial performance in...

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple ther...

Medincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments acr...
Back to Newsroom